{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=New+Onset+Type+1+Diabetes+Mellitus&page=2",
    "query": {
      "condition": "New Onset Type 1 Diabetes Mellitus",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=New+Onset+Type+1+Diabetes+Mellitus&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=New+Onset+Type+1+Diabetes+Mellitus&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T10:55:41.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00529191",
      "title": "Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "10 Years to 19 Years"
      },
      "enrollment_count": 40,
      "start_date": "2007-07",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-13",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529191"
    },
    {
      "nct_id": "NCT00905073",
      "title": "Low Dose Cyclosporin and Methotrexate Therapy in Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "cyclosporin and methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 8,
      "start_date": "1990-02",
      "completion_date": "1994-06",
      "has_results": false,
      "last_update_posted_date": "2011-04-13",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00905073"
    },
    {
      "nct_id": "NCT07670650",
      "title": "PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes (T1D)"
      ],
      "interventions": [
        {
          "name": "SAB-142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "5 Years to 40 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-09-01",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07670650"
    },
    {
      "nct_id": "NCT04598893",
      "title": "Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Teplizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Provention Bio, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "9 Years to 19 Years"
      },
      "enrollment_count": 188,
      "start_date": "2020-10-26",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 25,
      "location_summary": "San Diego, California • San Francisco, California • Walnut Creek, California + 22 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04598893"
    },
    {
      "nct_id": "NCT02971202",
      "title": "Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Maturity-Onset Diabetes of the Young, Type 2",
        "MODY2",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Hyperinsulinemic, euglycemic clamp",
          "type": "DRUG"
        },
        {
          "name": "20% dextrose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "13 Years to 51 Years"
      },
      "enrollment_count": 33,
      "start_date": "2016-12",
      "completion_date": "2019-02",
      "has_results": true,
      "last_update_posted_date": "2019-08-01",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02971202"
    },
    {
      "nct_id": "NCT02093221",
      "title": "Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "180 mg/kg Alpha1-PI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "90 mg/kg Alpha1-PI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 76,
      "start_date": "2014-03",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02093221"
    },
    {
      "nct_id": "NCT00100178",
      "title": "New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Mycophenolate mofeteil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Daclizumab (DZB)",
          "type": "DRUG"
        },
        {
          "name": "Placebo control for Mycophenolate mofeteil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Placebo control for Daclizumab (DZB)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 126,
      "start_date": "2004-05",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2020-05-05",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100178"
    },
    {
      "nct_id": "NCT00678886",
      "title": "Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "otelixizumab infusion plus physician determined standard of care",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo infusion plus physician determined standard of care",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 272,
      "start_date": "2008-07-29",
      "completion_date": "2012-01-31",
      "has_results": true,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678886"
    },
    {
      "nct_id": "NCT03895437",
      "title": "Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "TOL-3021",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TOL-3021 Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Tolerion, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 78,
      "start_date": "2019-06-17",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 23,
      "location_summary": "San Diego, California • San Francisco, California • San Mateo, California + 20 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03895437"
    },
    {
      "nct_id": "NCT00129259",
      "title": "Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Anti-CD3 mAb",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diabetes Standard of Care Treatment",
          "type": "OTHER"
        },
        {
          "name": "Iron supplementation",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "8 Years to 30 Years"
      },
      "enrollment_count": 83,
      "start_date": "2005-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-22",
      "last_synced_at": "2026-10-08T10:55:41.775Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129259"
    }
  ]
}